206 related articles for article (PubMed ID: 26054103)
1. Relevance of parathyroid hormone (PTH), vitamin 25(OH)D3, calcitonin (CT), bone metabolic markers, and bone mass density (BMD) in 860 female cases.
Zhang M; Li Y; Ma Q; Mao W; Gao Y; Liu Y; Liang B
Clin Exp Obstet Gynecol; 2015; 42(2):129-32. PubMed ID: 26054103
[TBL] [Abstract][Full Text] [Related]
2. [Prevention and treatment of aromatase inhibitor-associated bone loss by shugan jiangu recipe in postmenopausal women with breast cancer: a clinical study].
Li YQ; Sun H; Xue D; Xu YC; Li ZD; Wang W; Li PP
Zhongguo Zhong Xi Yi Jie He Za Zhi; 2014 Sep; 34(9):1064-8. PubMed ID: 25335329
[TBL] [Abstract][Full Text] [Related]
3. Effect of intermittent administration of 200 IU intranasal salmon calcitonin and low doses of 1alpha(OH) vitamin D3 on bone mineral density of the lumbar spine and hip region and biochemical bone markers in women with postmenopausal osteoporosis: a pilot study.
Kaskani E; Lyritis GP; Kosmidis C; Galanos A; Andypas G; Chorianopoulos K; Giagiosis A; Iliadou K; Karagianis A; Katsimichas K; Koskinas A; Matsouka K
Clin Rheumatol; 2005 Jun; 24(3):232-8. PubMed ID: 15647969
[TBL] [Abstract][Full Text] [Related]
4. Bone biomarkers in patients with chronic traumatic spinal cord injury.
Sabour H; Norouzi Javidan A; Latifi S; Larijani B; Shidfar F; Vafa MR; Heshmat R; Emami Razavi H
Spine J; 2014 Jul; 14(7):1132-8. PubMed ID: 24139865
[TBL] [Abstract][Full Text] [Related]
5. Effects of PTH (1-84) on bone quality in a validated model of osteoporosis due to androgenic deprivation.
Martín-Fernández M; Martínez E; Díaz-Curiel M; Guede D; Caeiro JR; De la Piedra C
Aging Male; 2014 Mar; 17(1):42-50. PubMed ID: 23914846
[TBL] [Abstract][Full Text] [Related]
6. Bone mineral metabolism is normal in non-insulin-dependent diabetes mellitus.
Sosa M; Dominguez M; Navarro MC; Segarra MC; Hernández D; de Pablos P; Betancor P
J Diabetes Complications; 1996; 10(4):201-5. PubMed ID: 8835919
[TBL] [Abstract][Full Text] [Related]
7. Correlation of Osteoporosis in Patients With Newly Diagnosed Type 2 Diabetes: A Retrospective Study in Chinese Population.
Wen Y; Li H; Zhang X; Liu P; Ma J; Zhang L; Zhang K; Song L
Front Endocrinol (Lausanne); 2021; 12():531904. PubMed ID: 34054717
[TBL] [Abstract][Full Text] [Related]
8. Relationship between biochemical markers and radial cortical bone changes in hemodialysis patients.
Fujimori A; Okada S; Sakai M; Tome K; Fukagawa M
Nephron Clin Pract; 2011; 118(4):c375-9. PubMed ID: 21325869
[TBL] [Abstract][Full Text] [Related]
9. Mechanisms of bone loss after cardiac transplantation.
Guo CY; Johnson A; Locke TJ; Eastell R
Bone; 1998 Mar; 22(3):267-71. PubMed ID: 9514219
[TBL] [Abstract][Full Text] [Related]
10. A randomized controlled trial to compare the efficacy of cyclical parathyroid hormone versus cyclical parathyroid hormone and sequential calcitonin to improve bone mass in postmenopausal women with osteoporosis.
Hodsman AB; Fraher LJ; Watson PH; Ostbye T; Stitt LW; Adachi JD; Taves DH; Drost D
J Clin Endocrinol Metab; 1997 Feb; 82(2):620-8. PubMed ID: 9024265
[TBL] [Abstract][Full Text] [Related]
11. Reference values for bone metabolism in a Japanese cohort survey randomly sampled from a basic elderly resident registry.
Tokida R; Uehara M; Nakano M; Suzuki T; Sakai N; Ikegami S; Takahashi J; Nakamura Y; Kato H
Sci Rep; 2021 Apr; 11(1):7822. PubMed ID: 33837266
[TBL] [Abstract][Full Text] [Related]
12. Activity or mass concentration of bone-specific alkaline phosphatase as a marker of bone formation.
Avbersek-Luznik I; Gmeiner Stopar T; Marc J
Clin Chem Lab Med; 2007; 45(8):1014-8. PubMed ID: 17579570
[TBL] [Abstract][Full Text] [Related]
13. Effects of denosumab on bone turnover markers in postmenopausal osteoporosis.
Eastell R; Christiansen C; Grauer A; Kutilek S; Libanati C; McClung MR; Reid IR; Resch H; Siris E; Uebelhart D; Wang A; Weryha G; Cummings SR
J Bone Miner Res; 2011 Mar; 26(3):530-7. PubMed ID: 20839290
[TBL] [Abstract][Full Text] [Related]
14. Serum TRACP 5b is a useful marker for monitoring alendronate treatment: comparison with other markers of bone turnover.
Nenonen A; Cheng S; Ivaska KK; Alatalo SL; Lehtimäki T; Schmidt-Gayk H; Uusi-Rasi K; Heinonen A; Kannus P; Sievänen H; Vuori I; Väänänen HK; Halleen JM
J Bone Miner Res; 2005 Oct; 20(10):1804-12. PubMed ID: 16355501
[TBL] [Abstract][Full Text] [Related]
15. Skeletal responsiveness to parathyroid hormone in pseudohypoparathyroidism.
Kanatani M; Sugimoto T; Kaji H; Ikeda K; Chihara K
Eur J Endocrinol; 2001 Mar; 144(3):263-9. PubMed ID: 11248746
[TBL] [Abstract][Full Text] [Related]
16. Early postmenopausal bone loss is prevented by estrogen and partially by 1alpha-OH-vitamin D3: therapeutic effects of estrogen and/or 1alpha-OH-vitamin D3.
Gorai I; Chaki O; Taguchi Y; Nakayama M; Osada H; Suzuki N; Katagiri N; Misu Y; Minaguchi H
Calcif Tissue Int; 1999 Jul; 65(1):16-22. PubMed ID: 10369728
[TBL] [Abstract][Full Text] [Related]
17. Comparison of antiresorptive activities of ipriflavone, an isoflavone derivative, and elcatonin, an eel carbocalcitonin.
Fujita T; Fujii Y; Miyauchi A; Takagi Y
J Bone Miner Metab; 1999; 17(4):289-95. PubMed ID: 10575594
[TBL] [Abstract][Full Text] [Related]
18. Correlations of new markers of bone formation and resorption in kidney transplant recipients.
Małyszko J; Wołczyński S; Małyszko JS; Konstantynowicz J; Kaczmarski M; Myśliwiec M
Transplant Proc; 2003 Jun; 35(4):1351-4. PubMed ID: 12826157
[TBL] [Abstract][Full Text] [Related]
19. Mineral bone disorder and osteoporosis in hemodialysis patients.
Slouma M; Sahli H; Bahlous A; Laadhar L; Smaoui W; Rekik S; Gharsallah I; Sallami M; Moussa FB; Elleuch M; Cheour E
Adv Rheumatol; 2020 Feb; 60(1):15. PubMed ID: 32102689
[TBL] [Abstract][Full Text] [Related]
20. Tartrate-resistant acid phosphatase isoform 5a as an inflammation marker in end-stage renal disease.
Janckila AJ; Lederer ED; Price BA; Yam LT
Clin Nephrol; 2009 Apr; 71(4):387-96. PubMed ID: 19356371
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
